Bio & Pharma
SK Biopharm holds sales meeting for marketing Cenobamate in US
The S.Korean pharmaceutical company will strengthen sales of its epilepsy drug targeting US medical staff and patients
By Feb 16, 2023 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego.
The purpose of the event is to motivate sales organizations and share future visions among US pharmaceutical companies.
Since the release of Cenobamate, an epilepsy treatment, in the United States in 2020, SK Biopharm has held a national sales meeting annually.
The company claims to be the only South Korean drug company to organize such an event.
"This year, we will be able to enhance our potential and achieve sustainable growth by targeting sales towards local medical staff and patients who have not previously used Cenobamate," said Lee Dong-hoon, CEO of SK Biopharmaceuticals.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Bio & PharmaSK Biopharm begins clinical trials of wearable device for detecting epilepsyDec 14, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Biopharmaceuticals launches epilepsy drug in FranceDec 09, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Biopharma's epilepsy treatment posts impressive growth in USNov 11, 2022 (Gmt+09:00)
1 Min read -
Comment 0
LOG IN